Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RPR Lovenox line extensions in 1997 could include two new indications, new packages.

Executive Summary

RPR LOVENOX LINE EXTENSIONS IN 1997 COULD INCLUDE TWO NEW INDICATIONS as well as a new 30 mg ampule and multi-dose vial for the low molecular weight heparin product, Rhone-Poulenc Rorer VP Glenn Mattes told the Bear Stearns health care conference in New York City Sept. 12. Lovenox (enoxaparin) is already marketed for prevention of deep vein thrombosis in hip and knee replacement surgery in packages of 10 prefilled syringes. The company expects approval for use in abdominal surgery "potentially by the end of this year" and hopes for clearance of an indication for treatment of DVT during 1997 as well, Mattes said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel